

## Ultomiris<sup>®</sup> (ravulizumab-cwvz) – New indication

- On March 25, 2024, <u>AstraZeneca announced</u> the FDA approval of <u>Ultomiris (ravulizumab-cwvz)</u>, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
- Ultomiris is also approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).
- The approval of Ultomiris for the new indication was based on an open-label study in 58 adult patients with anti-AQP4 antibody positive NMOSD. Efficacy assessments were based on a comparison of patients in the study with an external placebo control group from another study composed of a comparable population of adult patients with anti-AQP4 antibody positive NMOSD. The primary endpoint was the time to first adjudicated on-trial relapse.
  - No adjudicated on-trial relapses were observed in Ultomiris-treated patients during the treatment period, representing a statistically significant difference between Ultomiris and placebo in time to first adjudicated on-trial relapse (p < 0.0001). The hazard ratio for Ultomiris compared with placebo was 0.014 (95% CI: 0.000, 0.103), representing a 98.6% reduction in the risk of relapse.</p>
  - Ultomiris-treated patients experienced similar improvement in time to first adjudicated ontrial relapse with or without concomitant treatment.
- Ultomiris carries a boxed warning for serious meningococcal infections.
- The most common adverse reactions (≥ 10%) with Ultomiris use for NMOSD were COVID-19, headache, back pain, arthralgia, and urinary tract infection.
- The recommended intravenous Ultomiris loading and maintenance dosing in adult and pediatric patients, one month of age or older weighing 5 kg or greater, with PNH or aHUS, or in adult patients with gMG or NMOSD weighing 40 kg or greater, is based on the patient's body weight, with maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.
  - Refer to the Ultomiris drug label for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.